general situation

As a functional component of advanced skin care products, DNA photorepair enzyme can actively repair the gene damage caused by ultraviolet rays, which completely breaks through the current concept of "preventing" ultraviolet rays and is a radical solution to prevent ultraviolet rays from damaging. This is in line with the new concept of the transformation from skin care products to gene repair in the world.

Due to the destruction of the environment, the ultraviolet rays irradiated to the ground are more and more harmful to the human body. The incidence of skin cancer is increasing year by year, and the market for ultraviolet protection is becoming more and more popular. At present, the anti-ultraviolet products on the market mainly use blocking, isolation or scattering methods to reduce the damage of ultraviolet rays to the skin, and can not repair the damaged DNA in the skin.

DNA photorepair enzyme can actively repair the gene damage of skin cells caused by ultraviolet radiation, so it can inhibit the occurrence of erythema and skin inflammation caused by it. Inhibit the abnormal metabolic immune function caused by DNA damage, effectively resist the erosion of bacteria and parasites, delay aging, enhance skin metabolism and maintain cell vitality; It can also prevent skin cancer caused by ultraviolet damage.

Market prospect analysis

With the improvement of people's awareness of anti-ultraviolet, sunscreen products are constantly innovating and developing into functional skin care products to meet people's consumption needs. DNA photorepair enzyme plays an important role in repairing gene damage and preventing biological effects induced by gene damage, and will surely become the new favorite of functional sunscreen products.

investment scale

500-100000 RMB.

technical superiority

At present, the rapid purification process and pilot production conditions have been established, and two national patents have been applied. It is the only unit engaged in the research and development of DNA photorepair enzyme in China.

Favorable conditions for investing in capital projects

As the only laboratory dedicated to the development and utilization of photorepair enzymes in China, we have absolute advantages in developing DNA photorepair enzyme products in China. But also has the following advantages

1. With independent intellectual property rights, the use of enzyme protein to enhance the health care function of cosmetics conforms to the new concept of international skin care development;

2. At present, there are such products abroad, which is conducive to the declaration of this product entering the market. However, the technical route of this project is established independently and is not affected by foreign patents. Our technology has the advantages of lower cost and higher yield.

3. Compared with biopharmaceutical development, this project has a short development cycle, easy to obtain national approval for listing, less investment, quick recovery and great market growth potential, especially the products with certain scientific and technological content have high added value and large profit space;

Due to high-tech technical barriers, product development cycle and patent protection, investment enterprises can monopolize the market for a long time.

So it is a very favorable opportunity to enter the market. If we can develop skin care products with repair function, we will get rich returns.

Technology transfer mode (cooperation mode)

In order to turn our achievements into products as soon as possible, we are willing to cooperate with investors in a flexible way. Specific interview methods.

2p-p-chloro-p -p6p-formaldehyde pyridine

3p-p ethyl p -(2p- hydroxyacetaldehyde) ---p4p-- formaldehyde p- 1, 3 thiazole bromide

-drug intermediate 2p-p-chloro-p -p6p-formaldehyde pyridine

The production process of Pppp, a pharmaceutical intermediate, is: starting from 2p-p formaldehyde pyridine, the product is obtained through three chemical steps, and the yield is over 60%. The technology is very mature, and the research group now has a process flow chart and a brief description of the equipment.

The raw material cost of producing the drug intermediate is about 20 thousand yuan/ton; The product price is about 60 thousand yuan/ton, and the economic benefit is very optimistic.

3p-p ethyl p -(2p- hydroxyacetaldehyde) ---p4p-- formaldehyde p- 1, 3 thiazole bromide

The production process of pharmaceutical intermediate pppp is completed by five experimental steps, and the technology is mature after pilot verification. At present, the foreign purchase price of this drug intermediate is very expensive, about 654.38+0.5 million yuan/ton. If the intermediate is produced according to the process designed by us, the price is only about 6.5438+0.8 million yuan/ton, which can save a lot of foreign exchange for the country and bring good economic benefits to enterprises.